Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2021;384:18 de febrero. [Ref.ID 103836]

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal.S, Plested JS, Zhu M, Cloney-Clark S, Zho H, Smith G, Patel N, et al.. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020;383:2320-32. [Ref.ID 103813]

Cortizo G. Así descubrió la empresa que fabrica la vacuna de Novavax para Europa que les habían robado 9,7 millones de euros con 'el fraude del CEO'. eldiario.es 2020:3 de diciembre. [Ref.ID 103801]

Dal-Ré R, Caplan AL, Gluud C, Porcher R. Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine. Ann Intern Med 2020:20 de noviembre. [Ref.ID 103783]

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020;396:13 de octubre. [Ref.ID 103744]

Parsons L. Novavax reports promising phase 1 results for coronavirus vaccine. PMLiVE 2020:5 de agosto. [Ref.ID 103702]

Taylor P. Novavax COVID-19 vaccine bags record $384m funding from CEPI. PMLiVE 2020:12 de mayo. [Ref.ID 103623]

PM Group. Developing a COVID-19 vaccine. PMLiVE 2020:28 de abril. [Ref.ID 103606]

Parsons L. CEPI says $2bn is needed for COVID-19 vaccine development. PMLiVE 2020:16 de marzo. [Ref.ID 103550]